chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 68.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, Drug ineffective, SARS-CoV-2 test
Clinical narrative: Pfizer/BioNTech Dose Number: 3 14Nov2021/ Treatment of COVID-19 04Jun2022; Pfizer / BioNTech Dose Number: 3 14Nov2021/ Treatment of COVID-19 04Jun2022; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 69-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 14Nov2021 as dose 3 (booster), single (Batch/Lot number: unknown) at the age of 68 years for covid-19 immunisation; coviD-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown) and as dose 2, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "scoliosis" (unspecified if ongoing), notes: Other medical history: scoliosis/ablation for atrial flutter; "ablation for atrial flutter" (unspecified if ongoing), notes: Other medical history: scoliosis/ablation for atrial flutter. Concomitant medication(s) included: CRESTOR, start date: 30Sep2020, stop date: 18Jun2022; VIT D [COLECALCIFEROL]. Past drug history included: Plaquenil, reaction(s): "Known allergies: plaquenil - prolonged qtc", notes: Known allergies: plaquenil - prolonged qtc. The following information was reported: COVID-19 (medically significant) with onset 05Jun2022, outcome "not recovered", described as "Pfizer / BioNTech Dose Number: 3 14Nov2021/ Treatment of COVID-19 04Jun2022"; DRUG INEFFECTIVE (medically significant) with onset 05Jun2022, outcome "not recovered", described as "Pfizer/BioNTech Dose Number: 3 14Nov2021/ Treatment of COVID-19 04Jun2022". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (05Jun2022) Positive, notes: I tested positive for Covid 19 on the 5th of June. Therapeutic measures were taken as a result of drug ineffective, covid-19. The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.
Age: 62.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, SARS-CoV-2 test, Vaccination failure
Clinical narrative: Covid rebound. Tested negative 11Jun2022 Symptoms started again 18Jun2022 tested positive 19Jun2022; Covid rebound. Tested negative 11Jun2022 Symptoms started again 18Jun2022 tested positive 19Jun2022; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 62-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 01Mar2021 as dose 1, single (Lot number: EN6202), on 22Mar2021 as dose 2, single (Lot number: EP7534) and on 14Oct2021 as dose 3 (booster), single (Lot number: 301358A) at the age of 62 years for covid-19 immunisation. The patient's relevant medical history was not reported. Concomitant medication(s) included: PROZAC; WELLBUTRIN.  The following information was reported: VACCINATION FAILURE (medically significant), COVID-19 (medically significant), outcome "unknown" and all described as "Covid rebound. Tested negative 11Jun2022 Symptoms started again 18Jun2022 tested positive 19Jun2022". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (11Jun2022) Negative; (19Jun2022) Positive. Therapeutic measures were taken as a result of vaccination failure, covid-19. Concomitant medication(s) in 2 weeks included PROZAC and WELLBUTRIN. The patient had no known alleriges. The patient took Paxlovid for COVID 19 Treatment. The treatment start date was reported as 07Jun2022 and stop date was 10Jun2022.
Age: 82.0
Sex: M
Vaccine: COVID19
Symptoms: Blood test, Chest discomfort
Clinical narrative: I took the Pfizer Vaccine (unspecified vaccine) this morning and I am not having pain but I am having pressure in the chest area; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  An 82-year-old male patient received BNT162b2 (BNT162B2), on 18Jun2022 as dose number unknown, single (Batch/Lot number: unknown) at the age of 82 years for covid-19 immunisation. The patient's relevant medical history included: "Hard of hearing" (unspecified if ongoing), notes: Hard of hearing. The patient took concomitant medications. The following information was reported: CHEST DISCOMFORT (non-serious) with onset 18Jun2022, outcome "unknown", described as "I took the Pfizer Vaccine (unspecified vaccine) this morning and I am not having pain but I am having pressure in the chest area". The patient underwent the following laboratory tests and procedures: Blood test: Unknown Result, notes: consumer stated, "Well, I have blood test.". Therapeutic measures were not taken as a result of chest discomfort.  Additional information:consumer stated, "Okay, I took the Pfizer Vaccine (further consumer clarified as Pfizer vaccine) this morning, the Pfizer right and I am having, I am not having pain but I am having pressure in the chest area, so would that be dangerous." Consumer stated, "I am a little hard of hearing.In case, consumer was informed to visit nearest Facility, Emergency Room or Pharmacist. In response to MI operational timing consumer stated, "Okay, so I can't dial right now.".Vaccination date, consumer stated, "It was today, we had at all (facility name withheld).".When probed medication starting date, consumer stated, "Which medication I am not taking (Paxlovid) that.".When probed if took Paxlovid medication, consumer stated, "No sir.".When probed for other medical condition, consumer stated, "Yes, I have, I am having."When probed if taking any other medication (concomitant medication) names, consumer stated, "Oh Yes I have gotten lots of medications." (Further not clarified).When probed for any laboratory test performed, consumer stated, "Well, I have blood test." (Further not clarified).When probed if all lab result were relevant, consumer stated, "Yes.".Any treatment for the event occurred, consumer stated, "No, I don't.". Dosage and Relevant Information:Batch/lot number: Unknown. Is report related to a study or programme : No.Other Conditions: Yes.Is Unspecified Vaccine a Pfizer product : Yes.Reason for no lot number: of Unspecified Vaccine: Other: LOT#: Unspecified Vaccine.Unspecified Vaccine manufacturer: unspecified. Expiry Date of Unspecified Vaccine: Unknown.  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.
Age: 50.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, Drug ineffective
Clinical narrative: Treatment of COVID-19; Treatment of COVID-19; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 52-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 24Mar2021 as dose 1, single (Lot number: ER8730), on 15Apr2021 as dose 2, single (Lot number: ER8731) and on 28Nov2021 as dose 3 (booster), single (Lot number: 330308D) at the age of 50 years for covid-19 immunisation. The patient's relevant medical history was not reported. There were no concomitant medications. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "unknown" and all described as "Treatment of COVID-19". Therapeutic measures were taken as a result of drug ineffective, covid-19. Anti viral details: product=COVID 19 Treatment, brand=Paxlovid, Treatment start date=07Jun2022, treatment stop date=12Jun2022.
Age: 68.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, Vaccination failure
Clinical narrative: COVID-19 Treatment; COVID-19 Treatment; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 69-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 04Mar2021 at 11:00 as dose 1, single (Batch/Lot number: unknown), in right arm, on 01Apr2021 at 11:00 as dose 2, single (Batch/Lot number: unknown), in right arm and on 17Oct2021 at 16:00 as dose 3 (booster), single (Batch/Lot number: unknown) at the age of 68 years, in right arm for covid-19 immunisation; coviD-19 vaccine mrna (mrna 1273) (MODERNA COVID-19 VACCINE), on 01May2022 at 12:00 as dose 4 (booster), single (Batch/Lot number: unknown), in right arm for covid-19 immunisation. The patient's relevant medical history included: "Asthma" (unspecified if ongoing); "Hashimoto" (unspecified if ongoing), notes: Hashimoto; "Known allergies: Shellfish" (unspecified if ongoing). Concomitant medication(s) included: FLUTICASONE PROPIONATE, start date: 31Oct2021. The following information was reported: COVID-19 (medically significant), VACCINATION FAILURE (medically significant) all with onset Jun2022, outcome "unknown" and all described as "COVID-19 Treatment". Therapeutic measures were taken as a result of covid-19, vaccination failure.  Clinical information: Anti-viral details: Product: COVID-19 Treatment, Brand: Paxlovid, Treatment Start Date: 05Jun2022, Treatment Stop Date: 09Jun2022, Indication: Treatment of COVID-19.   The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.
Age: 41.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, Drug ineffective, SARS-CoV-2 test
Clinical narrative: COVID-19 Treatment; COVID-19 Treatment; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 42-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 29Mar2021 as dose number unknown, single (Lot number: er8732), in left arm and on 19Apr2021 as dose number unknown, single (Lot number: ew0164) at the age of 41 years, in left arm for covid-19 immunisation; coviD-19 vaccine mrna (mrna 1273) (MODERNA COVID-19 VACCINE), on 25Oct2021 as dose number unknown, single (Lot number: 032f21a), in left arm for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant) with onset Jun2022, outcome "unknown", COVID-19 (medically significant) with onset Jun2022, outcome "not recovered" and all described as "COVID-19 Treatment". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (Jun2022) Negative, notes: took Paxlovid from 06Jun- 11Jun had negative test; (19Jun2022) positive. Therapeutic measures were taken as a result of drug ineffective, covid-19.  Additional information: The patient was not taking any other medications/products within 2 weeks of starting COVID-19 treatment.
Age: 68.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, Drug ineffective
Clinical narrative: COVID 19 Treatment; COVID 19 Treatment; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 68-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 19Jan2021 at 12:15 as dose 1, single (Lot number: EL9263), in right arm, on 17Feb2021 at 12:30 as dose 2, single (Lot number: EL9267), in right arm and on 25Sep2021 at 12:00 as dose 3 (booster), single (Lot number: FF2588) at the age of 68 years, in left arm for covid-19 immunisation. The patient's relevant medical history included: "Diabetes" (unspecified if ongoing); "Stroke" (unspecified if ongoing); "Cholesterol" (unspecified if ongoing); "Heart" (unspecified if ongoing), notes: Heart. Concomitant medication(s) included: PLAVIX. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset 17Jun2022 at 08:00, outcome "unknown" and all described as "COVID 19 Treatment". Therapeutic measures were taken as a result of drug ineffective, covid-19.The patient previously received a COVID-19 Vaccine. AE resulted in none of the above. other medication in 2weeks product included Diabetes cholesterol Plavix antidepressants. Treatment started on 06Jun2022 and stopped on 09Jun2022.
Age: 57.0
Sex: F
Vaccine: COVID19
Symptoms: Immunisation reaction, Pruritus, Psoriatic arthropathy, Skin disorder, Skin papilloma
Clinical narrative: Psoriatic arthritis aggravated; Skin disorder; Warts; Localized itching; Vaccination adverse reaction; This is a solicited report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient. Other Case identifier(s): 22K-163-4433179-00.  A 57-year-old female patient received BNT162b2 (BNT162B2), on 01Mar2021 as dose 1, single (Batch/Lot number: unknown), on 01Apr2021 as dose 2, single (Batch/Lot number: unknown) and on 01Sep2021 as dose 3 (booster), single (Batch/Lot number: unknown) at the age of 57 years, all intramuscular for covid-19 immunisation; adalimumab (HUMIRA), since 2002 (Batch/Lot number: unknown) at 40 mg (40 mg, (cf)), subcutaneous for psoriatic arthropathy. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: IMMUNISATION REACTION (non-serious) with onset 2021, outcome "unknown", described as "Vaccination adverse reaction"; PSORIATIC ARTHROPATHY (medically significant), outcome "unknown", described as "Psoriatic arthritis aggravated"; SKIN DISORDER (non-serious), outcome "not recovered"; SKIN PAPILLOMA (non-serious), outcome "not recovered", described as "Warts"; PRURITUS (non-serious), outcome "unknown", described as "Localized itching". The action taken for adalimumab was unknown.  Clinical Course: it was unknown if patient was enrolled in a covid-19 vaccine trial.  Causality for Humira: The reporter's causality for the event(s) of warts/blemishes around waist and back/they itchy unknown onset and warts/blemishes around waist and back/they itchy unknown onset with Humira(Adalimumab) was no reasonable possibility and for the event vaccination adverse reaction, localized itching, skin disorder, psoriatic arthritis aggravated was not provided at the time of this report. Causality for Pfizer BioNTech Covid-19 Vaccine (Tozinameran): The reporter's assessment of the causal relationship of "psoriatic arthritis aggravated", "skin disorder", "warts" and "localized itching" with the suspect product(s) BNT162b2 was not provided at the time of this report. Since no determination has been received, the case is managed based on the company causality assessment. The reporter considered "vaccination adverse reaction" related to BNT162b2.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.; Sender's Comments: As there is limited information in the case provided, the causal association between the events and the suspect drug cannot be excluded. The case will be reassessed once new information is available.
Age: 44.0
Sex: F
Vaccine: COVID19
Symptoms: Urticaria
Clinical narrative: rash trunk; face red; fever; Worsened; Eyelid rash; Burning sensation in face; Swelling of face; Urticaria localized; pain in face; discomfort/Face was stretched to limit and really hurt, Uncomfortable; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient. Other Case identifier(s): 22K-163-4429208-00.  A 44-year-old female patient received BNT162b2 (BNT162B2), on 29Apr2022 as dose 3 (booster), single (Lot number: FK9894) at the age of 44 years intramuscular for covid-19 immunisation; adalimumab (HUMIRA), on 04May2022 (Batch/Lot number: unknown) subcutaneous for rheumatoid arthritis, ankylosing spondylitis; diphtheria vaccine toxoid, pertussis vaccine acellular, tetanus vaccine toxoid (TDAP), on 29Apr2022 as dose number unknown, single (Batch/Lot number: unknown) for immunisation. The patient's relevant medical history included: "Ankylosing Spondylitis" (unspecified if ongoing); "Epilepsy" (unspecified if ongoing); "Rheumatoid Arthritis" (unspecified if ongoing); "Gerd" (unspecified if ongoing); "Interstitial Cystitis" (unspecified if ongoing); "Restless Leg" (unspecified if ongoing). Concomitant medication(s) included: PREGABALIN; ESTRADIOL; KEPPRA [LEVETIRACETAM]; PLAQUENIL [HYDROXYCHLOROQUINE SULFATE]; ZYRTEC [CETIRIZINE HYDROCHLORIDE]; CLARITIN [LORATADINE]; TAGAMET [CIMETIDINE]; PHENOXYMETHYLPENICILLIN POTASSIUM. Past drug history included: Levofloxacin, reaction(s): "Levofloxacin Allergy"; Diltiazem, reaction(s): "Diltiazem allergy"; Furosemide, reaction(s): "Furosemide Allergy". Vaccination history included: comirnaty (dose 1, lot no.EW0151, Intramuscular), administration date: 05Apr2021, for covid-19 immunization; comirnaty (dose 2, lot no. EA6207, Intramuscular), administration date: 15Mar2022, for covid-19 immunization; Zoster vaccine recombinant adjuvanted, reaction(s): "Zoster Vaccine Recombinant Adjuvanted Allergy". The following information was reported: BURNING SENSATION (non-serious) with onset 05May2022, outcome "not recovered", described as "Burning sensation in face"; EYELID RASH (non-serious) with onset 05May2022, outcome "not recovered"; SWELLING FACE (non-serious) with onset 05May2022, outcome "not recovered", described as "Swelling of face"; URTICARIA (non-serious) with onset 05May2022, outcome "not recovered", described as "Urticaria localized"; DISCOMFORT (non-serious) with onset 05May2022, outcome "not recovered", described as "discomfort/Face was stretched to limit and really hurt, Uncomfortable"; FACIAL PAIN (non-serious) with onset 05May2022, outcome "not recovered", described as "pain in face"; RASH (non-serious), outcome "unknown", described as "rash trunk"; ERYTHEMA (non-serious), outcome "not recovered", described as "face red"; PYREXIA (non-serious), outcome "unknown", described as "fever"; CONDITION AGGRAVATED (non-serious), outcome "unknown", described as "Worsened". Relevant laboratory tests and procedures are available in the appropriate section. The action taken for adalimumab was unknown.   Follow-up attempts are completed. No further information is expected.
Sex: F
Vaccine: COVID19, UNK
Symptoms: Affect lability, Decreased appetite, Gingival pain, Vaccination site hypersensitivity
Clinical narrative: Patient reports she arm is more sensitive this time with he 2nd COVID booster shot; gum sensitivity; Patient also reports emotional lability where she may be laughing, but is also crying and feels sad simultaneously; Patient also reports low appetite since starting Lenvima; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient. Other Case identifier(s): EC-2022-112870.  A 69-year-old female patient received BNT162b2 (BNT162B2), as dose 2 (booster), single (Batch/Lot number: unknown) for covid-19 immunization; lenvatinib mesilate (LENVIMA), since 07Apr2022 (Batch/Lot number: unknown) at 14 mg. The patient's relevant medical history included: "endometrial cancer" (unspecified if ongoing), notes: C54.1. The patient's concomitant medications were not reported. Past drug history included: Keytruda. Vaccination history included: Covid-19 vaccine (DOSE X; MANUFACTURER UNKNOWN), for covid-19 immunisation. The following information was reported: VACCINATION SITE HYPERSENSITIVITY (non-serious), outcome "unknown", described as "Patient reports she arm is more sensitive this time with he 2nd COVID booster shot"; GINGIVAL PAIN (non-serious), outcome "unknown", described as "gum sensitivity"; AFFECT LABILITY (non-serious), outcome "unknown", described as "Patient also reports emotional lability where she may be laughing, but is also crying and feels sad simultaneously"; DECREASED APPETITE (non-serious), outcome "unknown", described as "Patient also reports low appetite since starting Lenvima". The action taken for lenvatinib mesilate was unknown.  Additional information: Patient received the Pfizer brand 2nd booster. Patient reports gum sensitivity. Her issue with small toe was not an in grown toenail and HCP is assisting he with fixing that issue. She also reports difficulty when trying to pop her ears as she used to. Patient uses saline nose spray to help with this issue. Patient also reports emotional lability where she may be laughing, but is also crying and feels sad simultaneously. Patient also reports low appetite since starting Lenvima. She feels her overall nutrition is still good at this time. She does think these things are related to Lenvima.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Age: 82.0
Sex: F
Vaccine: COVID19, UNK
Symptoms: Drug ineffective, Suspected COVID-19, Upper respiratory tract congestion, Upper-airway cough syndrome
Clinical narrative: Upper respiratory tract congestion; voice congestion with postnasal drip; Drug ineffective; Covid-19; This is a solicited report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient. Other Case identifier(s): 22K-163-4433494-00.  Solicited report by a consumer of an 82-year-old female with events of non-serious voice congestion with post nasal drip and Covid-19 with Humira (ADALIMUMAB). The patient received BNT162b2 (BNT162B2), on 03Mar2021 as dose 1, single (Batch/Lot number: unknown), on 24Mar2021 as dose 2, single (Batch/Lot number: unknown) and on 25Sep2021 as dose 3 (booster), single (Batch/Lot number: unknown) at the age of 82 years, all intramuscular for covid-19 immunisation; adalimumab (HUMIRA), (Lot number: 1162124) at citrate free, subcutaneous for rheumatoid arthritis. There was no reported medical history and concomitant medications. On an unknown date, the patient experienced voice congestion/Upper respiratory tract congestion with post nasal drip/ Upper-airway cough syndrome. In Mar2021, the patient experienced Covid-19 and Drug ineffective. It was unknown if patient was enrolled in a covid-19 vaccine trial. The action taken for adalimumab was unknown. The reporter's causality for event(s) of voice congestion with post nasal drip unknown onset and voice congestion with post nasal drip unknown onset with Humira (ADALIMUMAB) was no reasonable possibility (Not Related) and not reported for event Covid-19 and Drug ineffective. The reporter's causality for the event(s) "covid-19", "upper respiratory tract congestion" and "voice congestion with postnasal drip with BNT162b2 was Possible and not reported for Drug ineffective.  The lot number for [BNT162b2], was not provided and will be requested during follow up.; Sender's Comments: The reported Covid 19 positive after both the doses of  COVID-19 immunization is considered ineffective of BNT162B2, and the Company cannot completely exclude the possible causality between the reported events and BNT162B2 administration.
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, Drug ineffective, Pneumonia
Clinical narrative: COVID; COVID; Pneumonia; This is a solicited report received from contactable reporter(s) (Consumer or other non-HCP). The reporter is the patient. Other Case identifier(s): 22K-163-4434749-00.  An 81-year-old female patient received BNT162b2 (BNT162B2), as dose number unknown, single (Batch/Lot number: unknown) intramuscular for covid-19 immunisation; adalimumab (HUMIRA), (Batch/Lot number: unknown), subcutaneous for rheumatoid arthritis. The patient's relevant medical history and concomitant medications were not reported. It was unknown if patient was enrolled in a COVID-19 Vaccine Trial.   The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "not recovered" and all described as "COVID"; PNEUMONIA (medically significant), outcome "not recovered". The action taken for adalimumab was unknown.  The reporter's assessment of the causal relationship of "covid" and "pneumonia" with the suspect product(s) BNT162b2 was not provided at the time of this report. Since no determination has been received, the case is managed based on the company causality assessment.  The reporter's causality for the event (s) of COVID and Pneumonia with Humira (Adalimumab) was no reasonable possibility/ Not Related. The reporter's causality for the event (s) of COVID and Pneumonia with Pfizer BioNTech COVID-19 Vaccine was possible.  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.; Sender's Comments: Based on the limited information available, a possible contributory role of the Comirnaty vaccine cannot be completely excluded for the reported events.
Sex: F
Vaccine: COVID19
Symptoms: Cardiolipin antibody, Deep vein thrombosis, Fibula fracture
Clinical narrative: extensive right lower extremity DVT encompassing all vessels of the right leg extending up to the distal ivc; fibula fracture; This is a spontaneous report received from contactable reporter(s) (Other HCP) from a sales representative.  A 16-year-old female patient received BNT162b2 (BNT162B2), as dose 2, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Covid-19 vaccine (Dose 1, Manufacturer Unknown), for COVID-19 Immunization.  The following information was reported: DEEP VEIN THROMBOSIS (medically significant), outcome "unknown", described as "extensive right lower extremity DVT encompassing all vessels of the right leg extending up to the distal ivc"; FIBULA FRACTURE (medically significant), outcome "unknown". The patient underwent the following laboratory tests and procedures: Cardiolipin antibody: Positive.  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.; Sender's Comments: As there is limited information in the case provided, the causal association between the events deep vein thrombosis and fibula fracture and the suspect drug cannot be excluded. The case will be reassessed once new information is available.  The impact of this report on the benefit/risk profile of the Pfizer drug is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to Regulatory Authorities, Ethics Committees, and Investigators, as appropriate.
Sex: F
Vaccine: COVID19
Symptoms: Hidradenitis, Knee arthroplasty
Clinical narrative: knee replacement; Hidradenitis suppurativa flare up; This is a solicited report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient. Other Case identifier(s): 22K-163-4436002-00.  A 46-year-old female patient received BNT162b2 (BNT162B2), as dose number unknown, single (Batch/Lot number: unknown) intramuscular for Covid-19 immunization; adalimumab (HUMIRA), (Batch/Lot number: unknown), subcutaneous for hidradenitis. The patient's relevant medical history and concomitant medications were not reported.  The following information was reported: KNEE ARTHROPLASTY (medically significant), outcome "unknown", described as "knee replacement"; HIDRADENITIS (medically significant), outcome "unknown", described as "Hidradenitis suppurativa flare up". The action taken for adalimumab was unknown.  The reporter's assessment of the causal relationship of "knee replacement" and "hidradenitis suppurativa flare up" with the suspect product(s) BNT162b2 was not provided at the time of this report. Since no determination has been received, the case is managed based on the company causality assessment.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.; Sender's Comments: As there is limited information in the case provided, the causal association between the event and the suspect drug BNT162B2 cannot be excluded. The case will be reassessed once new information is available. The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to regulatory authorities, Ethics Committees, and Investigators, as appropriate.
Sex: M
Vaccine: COVID19
Symptoms: COVID-19, Drug ineffective, SARS-CoV-2 test
Clinical narrative: My 13-year-old son had it [COVID] twice, once after getting two doses of Pfizer.; My 13-year-old son had it [COVID] twice, once after getting two doses of Pfizer.; This is a spontaneous report received from non-contactable reporter(s) (Nurse).  A 13-year-old male patient received BNT162b2 (COMIRNATY), as dose 1, single (Batch/Lot number: unknown) and as dose 2, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "unknown" and all described as "My 13-year-old son had it [COVID] twice, once after getting two doses of Pfizer.". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: Positive.  Clinical information: Description of Event: Reader of a medical news site posted in the comment section of an article: "My 13-year-old son had it [COVID] twice, once after getting two doses of Pfizer."Name of Product: Comirnaty. Event took place after use of product. No additional information was provided. Event took place after use of product.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.; Sender's Comments: Based on the information in the case report and a plausible temporal relationship, a possible causal association between the events Covid 19 and Drug ineffective and suspect drug BNT162B2 cannot be excluded.
Sex: F
Vaccine: COVID19
Symptoms: Headache
Clinical narrative: headache about 12 hours after receiving COVID vaccine; This is a spontaneous report received from a contactable reporter(s) (Pharmacist).  A 5-year-old female patient received BNT162b2 (COMIRNATY), as dose number unknown, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: HEADACHE (non-serious), outcome "unknown", described as "headache about 12 hours after receiving COVID vaccine". No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Age: 32.0
Sex: F
Vaccine: COVID19
Symptoms: Abortion induced, Exposure during pregnancy, Foetal megacystis, Haemorrhage in pregnancy, Magnetic resonance imaging
Clinical narrative: I don't know if this is where I should report this. I am (original citizen), but live in (another country). I got all of my vaccines here. If there is somewhere else I should be reporting this, please let me know. I was 9 weeks pregnant when I got my 3rd covid shot. 2 weeks later I started having severe bleeding that lasted on and off throughout the rest of my pregnancy. My baby developed severe megacystis which got worse and worse, and I was eventually encouraged to terminate the pregnancy.
Age: 32.0
Sex: F
Vaccine: COVID19
Symptoms: Ultrasound antenatal screen
Clinical narrative: I don't know if this is where I should report this. I am (original citizen), but live in (another country). I got all of my vaccines here. If there is somewhere else I should be reporting this, please let me know. I was 9 weeks pregnant when I got my 3rd covid shot. 2 weeks later I started having severe bleeding that lasted on and off throughout the rest of my pregnancy. My baby developed severe megacystis which got worse and worse, and I was eventually encouraged to terminate the pregnancy.
Age: 74.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Feeling hot, Headache, Injection site pain, Irritability
Clinical narrative: Pain at injection site, extreme headache, Temperature 101 degrees, joint pain, nerve pain/irritated feels hot.
Age: 74.0
Sex: F
Vaccine: COVID19
Symptoms: Neuralgia
Clinical narrative: Pain at injection site, extreme headache, Temperature 101 degrees, joint pain, nerve pain/irritated feels hot.
Age: 86.0
Sex: F
Vaccine: COVID19
Symptoms: Antinuclear antibody increased, Arthralgia, C-reactive protein increased, Joint stiffness, Pain in extremity
Clinical narrative: Extremity and joint pain and stiffness, elevated CRP, ESR and ANA on 6/7/2022
Age: 86.0
Sex: F
Vaccine: COVID19
Symptoms: Red blood cell sedimentation rate increased
Clinical narrative: Extremity and joint pain and stiffness, elevated CRP, ESR and ANA on 6/7/2022
Age: 50.0
Sex: F
Vaccine: VARZOS
Symptoms: Arthralgia, Injection site pain, Mobility decreased
Clinical narrative: Site: Pain at Injection Site-Medium, Systemic: Joint Pain-Medium, Additional Details: Pain in shoulder with limited range of motion continuing over 3 months beyond admin date. Has visited chiropractor/orthopedics due to event which remains unresolved
Age: 17.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Injection site erythema, Injection site pain, Injection site rash, Injection site swelling
Clinical narrative: Site: Pain at Injection Site-Medium, Site: Redness at Injection Site-Medium, Site: Swelling at Injection Site-Medium, Systemic: Allergic: Itch (specify: facial area, extremeties)-Medium, Systemic: Allergic: Rash (specify: facial area, extremeties)-Medium, Systemic: Allergic: Rash Generalized-Medium, Systemic: Chills-Medium, Additional Details: patient noticed blisters and rash appearing at site of injection and also on the chest, it didn't get better and she decided to call the pharmacy, patient was recommended benadryl and tylenol pain relief and was also recommended to check with md
Age: 17.0
Sex: F
Vaccine: COVID19
Symptoms: Injection site vesicles, Pain, Pruritus, Rash
Clinical narrative: Site: Pain at Injection Site-Medium, Site: Redness at Injection Site-Medium, Site: Swelling at Injection Site-Medium, Systemic: Allergic: Itch (specify: facial area, extremeties)-Medium, Systemic: Allergic: Rash (specify: facial area, extremeties)-Medium, Systemic: Allergic: Rash Generalized-Medium, Systemic: Chills-Medium, Additional Details: patient noticed blisters and rash appearing at site of injection and also on the chest, it didn't get better and she decided to call the pharmacy, patient was recommended benadryl and tylenol pain relief and was also recommended to check with md
Age: 54.0
Sex: F
Vaccine: COVID19
Symptoms: Injected limb mobility decreased, Injection site pain, Injection site swelling
Clinical narrative: Site: Pain at Injection Site-Severe, Site: Swelling at Injection Site-Severe, Additional Details: Patient states she is unable to use her left arm
Age: 34.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Abortion spontaneous, Bacterial test positive, Blood urine, Exposure during pregnancy, Foetal death
Clinical narrative: 6/21/2022 Fetal demise & preterm delivery. The patient presented to emergency department (ED) for cramping & vaginal bleeding at 21 wk 2 days gestation pregnant. Sent to obstetrics (OB) for evaluation & after watched for a couple hours sent home. Returned to the ED complaining of having miscarried at home about 10 min prior to arrival. Arrived with only the deceased fetus (still in amniotic sac) delivered and still attached to placenta via umbilical cord. Once taken from her car to the ED the OB MD used ring forceps to assist in the delivery of the placenta.
Age: 34.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Foetal monitoring normal, Forceps delivery, Muscle spasms, Premature delivery, Urinary sediment present
Clinical narrative: 6/21/2022 Fetal demise & preterm delivery. The patient presented to emergency department (ED) for cramping & vaginal bleeding at 21 wk 2 days gestation pregnant. Sent to obstetrics (OB) for evaluation & after watched for a couple hours sent home. Returned to the ED complaining of having miscarried at home about 10 min prior to arrival. Arrived with only the deceased fetus (still in amniotic sac) delivered and still attached to placenta via umbilical cord. Once taken from her car to the ED the OB MD used ring forceps to assist in the delivery of the placenta.
Age: 34.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Urine analysis abnormal, Vaginal haemorrhage
Clinical narrative: 6/21/2022 Fetal demise & preterm delivery. The patient presented to emergency department (ED) for cramping & vaginal bleeding at 21 wk 2 days gestation pregnant. Sent to obstetrics (OB) for evaluation & after watched for a couple hours sent home. Returned to the ED complaining of having miscarried at home about 10 min prior to arrival. Arrived with only the deceased fetus (still in amniotic sac) delivered and still attached to placenta via umbilical cord. Once taken from her car to the ED the OB MD used ring forceps to assist in the delivery of the placenta.
Age: 25.0
Sex: F
Vaccine: COVID19, TDAP
Symptoms: Pain in extremity, Tenderness
Clinical narrative: after her tdap vaccine on 5/22/24 she had a sore arm for 5 days which was almost completely resolved. On 6/3/22 she had her pfizer covid booster and again developed a sore arm. this improved but she has a mild 3/10 continued pain with palpation and certain stretches. no numbness, tingling, or swelling.
Age: 36.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Autonomic neuropathy, Back pain, Balance disorder, Chest pain, Cognitive disorder
Clinical narrative: CHEST PAIN, PAIN IN LEFT ARM, PAIN IN BACK, LIGHTHEADIDNESS, PASSING OUT - 15 OCT 2021 BLOOD LOSS IN HANDS AND FEET WHEN EXPOSED TO COLD - SECONDARY ONSET REYNAUDS - 3 NOV 2021 ERRATIC AND HIGH HEART RATE WHEN RUNNING - 20 OCT 2021 TO CURRENT CHEST PAIN, PAIN LEFT ARMY, PAIN IN BACK, HEADACHE, 20 MIN PASSING OUT EPISODE, LIGHT HEADINESS - 24 JAN 2022 NERVE PAIN ACROSS BACK AND ARMS, TINGLING IN FEET AND HANDS, CONSTANT HEADACHE, DECLINED COGNITIVE FUNCTION, DIFFICULTY SWALLOWING, LIGHTHEADIDNESS, DIFFICULTY STANDING, LOSS OF BALANCE, DIARRIA, LOSS OF SENSATION OF BEING HUNGRY OR FULL, WEIGHT LOSS AND WEIGHT GAIN OF 15+ LBS IN 3 WEEK PERIODS, SKIN RASH ON LEGS THAT APPEARS AND DISAPPEARS,  muscle fasciculations, Dysesthesia,   suspect small fiber and autonomic neuropathy, dyspnea on exertion, exercise intolerance and other dysautonomic/small fiber symptoms
Age: 36.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Coproporphyrinogen increased, Decreased appetite, Diarrhoea, Dizziness, Dysaesthesia
Clinical narrative: CHEST PAIN, PAIN IN LEFT ARM, PAIN IN BACK, LIGHTHEADIDNESS, PASSING OUT - 15 OCT 2021 BLOOD LOSS IN HANDS AND FEET WHEN EXPOSED TO COLD - SECONDARY ONSET REYNAUDS - 3 NOV 2021 ERRATIC AND HIGH HEART RATE WHEN RUNNING - 20 OCT 2021 TO CURRENT CHEST PAIN, PAIN LEFT ARMY, PAIN IN BACK, HEADACHE, 20 MIN PASSING OUT EPISODE, LIGHT HEADINESS - 24 JAN 2022 NERVE PAIN ACROSS BACK AND ARMS, TINGLING IN FEET AND HANDS, CONSTANT HEADACHE, DECLINED COGNITIVE FUNCTION, DIFFICULTY SWALLOWING, LIGHTHEADIDNESS, DIFFICULTY STANDING, LOSS OF BALANCE, DIARRIA, LOSS OF SENSATION OF BEING HUNGRY OR FULL, WEIGHT LOSS AND WEIGHT GAIN OF 15+ LBS IN 3 WEEK PERIODS, SKIN RASH ON LEGS THAT APPEARS AND DISAPPEARS,  muscle fasciculations, Dysesthesia,   suspect small fiber and autonomic neuropathy, dyspnea on exertion, exercise intolerance and other dysautonomic/small fiber symptoms
Age: 36.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Dysphagia, Dyspnoea exertional, Dysstasia, Exercise tolerance decreased, Headache
Clinical narrative: CHEST PAIN, PAIN IN LEFT ARM, PAIN IN BACK, LIGHTHEADIDNESS, PASSING OUT - 15 OCT 2021 BLOOD LOSS IN HANDS AND FEET WHEN EXPOSED TO COLD - SECONDARY ONSET REYNAUDS - 3 NOV 2021 ERRATIC AND HIGH HEART RATE WHEN RUNNING - 20 OCT 2021 TO CURRENT CHEST PAIN, PAIN LEFT ARMY, PAIN IN BACK, HEADACHE, 20 MIN PASSING OUT EPISODE, LIGHT HEADINESS - 24 JAN 2022 NERVE PAIN ACROSS BACK AND ARMS, TINGLING IN FEET AND HANDS, CONSTANT HEADACHE, DECLINED COGNITIVE FUNCTION, DIFFICULTY SWALLOWING, LIGHTHEADIDNESS, DIFFICULTY STANDING, LOSS OF BALANCE, DIARRIA, LOSS OF SENSATION OF BEING HUNGRY OR FULL, WEIGHT LOSS AND WEIGHT GAIN OF 15+ LBS IN 3 WEEK PERIODS, SKIN RASH ON LEGS THAT APPEARS AND DISAPPEARS,  muscle fasciculations, Dysesthesia,   suspect small fiber and autonomic neuropathy, dyspnea on exertion, exercise intolerance and other dysautonomic/small fiber symptoms
Age: 36.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Heart rate increased, Heart rate irregular, Laboratory test abnormal, Loss of consciousness, Lymphocyte count decreased
Clinical narrative: CHEST PAIN, PAIN IN LEFT ARM, PAIN IN BACK, LIGHTHEADIDNESS, PASSING OUT - 15 OCT 2021 BLOOD LOSS IN HANDS AND FEET WHEN EXPOSED TO COLD - SECONDARY ONSET REYNAUDS - 3 NOV 2021 ERRATIC AND HIGH HEART RATE WHEN RUNNING - 20 OCT 2021 TO CURRENT CHEST PAIN, PAIN LEFT ARMY, PAIN IN BACK, HEADACHE, 20 MIN PASSING OUT EPISODE, LIGHT HEADINESS - 24 JAN 2022 NERVE PAIN ACROSS BACK AND ARMS, TINGLING IN FEET AND HANDS, CONSTANT HEADACHE, DECLINED COGNITIVE FUNCTION, DIFFICULTY SWALLOWING, LIGHTHEADIDNESS, DIFFICULTY STANDING, LOSS OF BALANCE, DIARRIA, LOSS OF SENSATION OF BEING HUNGRY OR FULL, WEIGHT LOSS AND WEIGHT GAIN OF 15+ LBS IN 3 WEEK PERIODS, SKIN RASH ON LEGS THAT APPEARS AND DISAPPEARS,  muscle fasciculations, Dysesthesia,   suspect small fiber and autonomic neuropathy, dyspnea on exertion, exercise intolerance and other dysautonomic/small fiber symptoms
Age: 36.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Monocyte count increased, Muscle contractions involuntary, Neuralgia, Neutrophil count increased, Pain in extremity
Clinical narrative: CHEST PAIN, PAIN IN LEFT ARM, PAIN IN BACK, LIGHTHEADIDNESS, PASSING OUT - 15 OCT 2021 BLOOD LOSS IN HANDS AND FEET WHEN EXPOSED TO COLD - SECONDARY ONSET REYNAUDS - 3 NOV 2021 ERRATIC AND HIGH HEART RATE WHEN RUNNING - 20 OCT 2021 TO CURRENT CHEST PAIN, PAIN LEFT ARMY, PAIN IN BACK, HEADACHE, 20 MIN PASSING OUT EPISODE, LIGHT HEADINESS - 24 JAN 2022 NERVE PAIN ACROSS BACK AND ARMS, TINGLING IN FEET AND HANDS, CONSTANT HEADACHE, DECLINED COGNITIVE FUNCTION, DIFFICULTY SWALLOWING, LIGHTHEADIDNESS, DIFFICULTY STANDING, LOSS OF BALANCE, DIARRIA, LOSS OF SENSATION OF BEING HUNGRY OR FULL, WEIGHT LOSS AND WEIGHT GAIN OF 15+ LBS IN 3 WEEK PERIODS, SKIN RASH ON LEGS THAT APPEARS AND DISAPPEARS,  muscle fasciculations, Dysesthesia,   suspect small fiber and autonomic neuropathy, dyspnea on exertion, exercise intolerance and other dysautonomic/small fiber symptoms
Age: 36.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Paraesthesia, Peripheral coldness, Porphyrins urine, Rash, Raynaud's phenomenon
Clinical narrative: CHEST PAIN, PAIN IN LEFT ARM, PAIN IN BACK, LIGHTHEADIDNESS, PASSING OUT - 15 OCT 2021 BLOOD LOSS IN HANDS AND FEET WHEN EXPOSED TO COLD - SECONDARY ONSET REYNAUDS - 3 NOV 2021 ERRATIC AND HIGH HEART RATE WHEN RUNNING - 20 OCT 2021 TO CURRENT CHEST PAIN, PAIN LEFT ARMY, PAIN IN BACK, HEADACHE, 20 MIN PASSING OUT EPISODE, LIGHT HEADINESS - 24 JAN 2022 NERVE PAIN ACROSS BACK AND ARMS, TINGLING IN FEET AND HANDS, CONSTANT HEADACHE, DECLINED COGNITIVE FUNCTION, DIFFICULTY SWALLOWING, LIGHTHEADIDNESS, DIFFICULTY STANDING, LOSS OF BALANCE, DIARRIA, LOSS OF SENSATION OF BEING HUNGRY OR FULL, WEIGHT LOSS AND WEIGHT GAIN OF 15+ LBS IN 3 WEEK PERIODS, SKIN RASH ON LEGS THAT APPEARS AND DISAPPEARS,  muscle fasciculations, Dysesthesia,   suspect small fiber and autonomic neuropathy, dyspnea on exertion, exercise intolerance and other dysautonomic/small fiber symptoms
Age: 36.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Small fibre neuropathy, Weight decreased, Weight increased, White blood cell count increased
Clinical narrative: CHEST PAIN, PAIN IN LEFT ARM, PAIN IN BACK, LIGHTHEADIDNESS, PASSING OUT - 15 OCT 2021 BLOOD LOSS IN HANDS AND FEET WHEN EXPOSED TO COLD - SECONDARY ONSET REYNAUDS - 3 NOV 2021 ERRATIC AND HIGH HEART RATE WHEN RUNNING - 20 OCT 2021 TO CURRENT CHEST PAIN, PAIN LEFT ARMY, PAIN IN BACK, HEADACHE, 20 MIN PASSING OUT EPISODE, LIGHT HEADINESS - 24 JAN 2022 NERVE PAIN ACROSS BACK AND ARMS, TINGLING IN FEET AND HANDS, CONSTANT HEADACHE, DECLINED COGNITIVE FUNCTION, DIFFICULTY SWALLOWING, LIGHTHEADIDNESS, DIFFICULTY STANDING, LOSS OF BALANCE, DIARRIA, LOSS OF SENSATION OF BEING HUNGRY OR FULL, WEIGHT LOSS AND WEIGHT GAIN OF 15+ LBS IN 3 WEEK PERIODS, SKIN RASH ON LEGS THAT APPEARS AND DISAPPEARS,  muscle fasciculations, Dysesthesia,   suspect small fiber and autonomic neuropathy, dyspnea on exertion, exercise intolerance and other dysautonomic/small fiber symptoms
Age: 81.0
Sex: M
Vaccine: COVID19
Symptoms: COVID-19
Clinical narrative: Patient developed COVID-19 after receiving vaccinations.
Age: 74.0
Sex: F
Vaccine: COVID19
Symptoms: Product storage error
Clinical narrative: Stored in freezer >2 weeks
Age: 48.0
Sex: M
Vaccine: COVID19
Symptoms: Extra dose administered, No adverse event
Clinical narrative: Patient came in for second Moderna booster. Vaccinator administered Moderna  booster. On consent form he wrote age of 50 with a date of birth 03/27/1972. Later changed 1972 to 1974. Individual received last three vaccines from a different facility. LPN and I phoned individual to confirm and he stated" My sister corrected my date of birth as we both were in a rush. It was an honest mistake, I thought I corrected it on the form to reflect my age". No adverse reaction noted- no treatment needed.
Age: 51.0
Sex: F
Vaccine: COVID19
Symptoms: Product storage error
Clinical narrative: Stored in freezer >2 weeks
Age: 70.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Hypoxia, Sepsis, Urinary tract infection
Clinical narrative: Sepsis, hypoxi and UTI, treated with iv antibiotics and fluids.
Age: 80.0
Sex: M
Vaccine: COVID19
Symptoms: Product storage error
Clinical narrative: Stored in freezer >2 weeks
Age: 81.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Dizziness, Dyspnoea, Fatigue, Heart rate irregular, Myocarditis
Clinical narrative: He got his vaccine, he had some fatigue, was doing well, and then roughly 5 days later he began to develop very substantial orthostatic hypotension pre and post prandial, light headedness, a lot of shortness of breath, and very noticeable irregular heart beat, and has had numerous episodes of that and getting better.  Over the last couple of days has been getting worse, more reactions.  It tends to vary with the temperature.  He had in the past very occasional orthostatic hypotension, very mild.  In cooler weather he has never gotten it.  It is bad right now, and wipes him out physically.   From the first symptoms it got worse and worse for a week, then started improving quickly, and in the last couple of days seems to be reversing again.    He thinks he is having indications of myocarditis, and is worried that it will go into something worse.  He has a friend who is having the exact same symptoms having had the 4th vaccine.    1st vaccine had fatigue and minor arm soreness, and slept a lot and went away after a couple of days.  He then had the next 2 and had no real problems to complain about.
Age: 81.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Orthostatic hypotension
Clinical narrative: He got his vaccine, he had some fatigue, was doing well, and then roughly 5 days later he began to develop very substantial orthostatic hypotension pre and post prandial, light headedness, a lot of shortness of breath, and very noticeable irregular heart beat, and has had numerous episodes of that and getting better.  Over the last couple of days has been getting worse, more reactions.  It tends to vary with the temperature.  He had in the past very occasional orthostatic hypotension, very mild.  In cooler weather he has never gotten it.  It is bad right now, and wipes him out physically.   From the first symptoms it got worse and worse for a week, then started improving quickly, and in the last couple of days seems to be reversing again.    He thinks he is having indications of myocarditis, and is worried that it will go into something worse.  He has a friend who is having the exact same symptoms having had the 4th vaccine.    1st vaccine had fatigue and minor arm soreness, and slept a lot and went away after a couple of days.  He then had the next 2 and had no real problems to complain about.